Onsala, undefined

Lars Ek

This inventor holds 1 USPTO granted patent. Top assignee: Aktiebolaget Hassle. Active years: 1976.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1976

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lars Ek - Innovator in Pharmaceutical Chemistry

Introduction

Lars Ek is a notable inventor based in Onsala, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic applications in treating heart diseases.

Latest Patents

Lars Ek holds a patent for "Phenoxy-hydroxypropylamines, their preparation, and method." This patent includes para-substituted phenoxy-hydroxypropylamines, which are characterized by a specific general formula. The compounds disclosed in this patent are designed to selectively block the .beta.-receptors of the heart, making them useful in treating heart diseases in both animals and humans. The patent outlines methods for the preparation of these compounds and their pharmaceutical applications.

Career Highlights

Lars Ek is associated with Aktiebolaget Hassle, where he has contributed to innovative research and development in the pharmaceutical sector. His work has led to advancements in the understanding and treatment of cardiovascular conditions.

Collaborations

Lars has collaborated with notable colleagues, including Arne Elof Brandstrom and Bengt Arne Ablad. Their combined expertise has fostered a productive research environment, leading to significant advancements in their field.

Conclusion

Lars Ek's contributions to pharmaceutical chemistry, particularly through his patent on phenoxy-hydroxypropylamines, highlight his role as an innovator in the industry. His work continues to impact the treatment of heart diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…